Skip to main content

Clinical Trials Using Radium Ra 223 Dichloride

Review the clinical trials studying radium ra 223 dichloride on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-7 of 7

Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 35 locations
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Status: Active
Location: 44 locations
Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Status: Active
Location: 18 locations
Bipolar Androgen Therapy and Radium-223 for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, MAT-RAD Trial
Status: Active
Location: 2 locations
Radium-223 in Biochemically Recurrent Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Radiation Therapy (Ra-223) for the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastasis Selected Using PSMA PET Scans
Status: Active
Location: University of California San Francisco, San Francisco, California
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: 3 locations